Expansion in EMEA follows the business’ success with Veeva CRM
throughout North America, Latin America, and Asia Pacific
BARCELONA, Spain–(BUSINESS WIRE)—Veeva
Systems (NYSE:VEEV) today announced that the Healthcare business of Merck
has selected Veeva
CRM to improve operating efficiency and commercial effectiveness in
Europe, Middle East, and Africa (EMEA). Building on the multi-year
partnership with Veeva and following its success throughout North
America, Latin America, and Asia Pacific, the business is now
standardizing on multichannel
Veeva CRM globally.
In addition to core Veeva CRM, the Healthcare business of Merck is
expanding use of Veeva
CLM, Veeva
CRM Approved Email, and Veeva
CRM MyInsights across the world. These solutions will enable the
business to deliver a seamless customer experience across all channels,
including face-to-face, email, and web.
“Understanding our customers and delivering them the right information
at the right time through the right channel is key to our commercial
strategy,” said Chetak Buaria, global head of commercial excellence of
the Healthcare business at Merck. “We are unifying on a single global
CRM solution to deliver on this vision with Veeva as our trusted global
partner.”
“Veeva is committed to helping life sciences companies drive effective
engagement with healthcare professionals,” said Paul Shawah, senior vice
president of Veeva
Commercial Cloud. “We are proud to team with the Healthcare business
of Merck on their important mission to bring innovative medicines to
market.”
Additional Information
For more on Veeva Vault CRM Suite,
visit: veeva.com/eu/CRM-suite
Connect
with Veeva on LinkedIn: linkedin.com/company/veeva-systems
Follow
@veeva_eu on Twitter: twitter.com/veeva_eu
Like
Veeva on Facebook: facebook.com/veevasystems
About Veeva Systems
Veeva Systems Inc. is the leader in cloud-based software for the global
life sciences industry. Committed to innovation, product excellence, and
customer success, Veeva serves more than 700 customers, ranging from the
world’s largest pharmaceutical companies to emerging biotechs. Veeva is
headquartered in the San Francisco Bay Area, with offices throughout
North America, Europe, Asia, and Latin America. For more information,
visit veeva.com/eu.
About Merck
Merck, a leading science and technology company, operates across
healthcare, life science and performance materials. Around 52,000
employees work to make a positive difference to millions of people’s
lives every day by creating more joyful and sustainable ways to live.
From advancing gene editing technologies and discovering unique ways to
treat the most challenging diseases to enabling the intelligence of
devices – the company is everywhere. In 2018, Merck generated sales of €
14.8 billion in 66 countries.
Scientific exploration and responsible entrepreneurship have been key to
Merck’s technological and scientific advances. This is how Merck has
thrived since its founding in 1668. The founding family remains the
majority owner of the publicly listed company. Merck holds the global
rights to the Merck name and brand. The only exceptions are the United
States and Canada, where the business sectors of Merck operate as EMD
Serono in healthcare, MilliporeSigma in life science, and EMD
Performance Materials.
Forward-looking Statements
This release contains forward-looking statements, including the market
demand for and acceptance of Veeva’s products and services, the results
from use of Veeva’s products and services, and general business
conditions, particularly in the life sciences industry. Any
forward-looking statements contained in this press release are based
upon Veeva’s historical performance and its current plans, estimates,
and expectations, and are not a representation that such plans,
estimates, or expectations will be achieved. These forward-looking
statements represent Veeva’s expectations as of the date of this press
announcement. Subsequent events may cause these expectations to change,
and Veeva disclaims any obligation to update the forward-looking
statements in the future. These forward-looking statements are subject
to known and unknown risks and uncertainties that may cause actual
results to differ materially. Additional risks and uncertainties that
could affect Veeva’s financial results are included under the captions,
“Risk Factors” and “Management’s Discussion and Analysis of Financial
Condition and Results of Operations,” in the company’s filing on Form
10-K for the period ended January 31, 2019. This is available on the
company’s website at veeva.com
under the Investors section and on the SEC’s website at sec.gov.
Further information on potential risks that could affect actual results
will be included in other filings Veeva makes with the SEC from time to
time.
Contacts
Roger Villareal
Veeva Systems
925-264-8885
roger.villareal@veeva.com
Kiran May
Veeva Systems
+44-796-643-2912
kiran.may@veeva.com